GH1 and cancer: Definitive data are lacking regarding the safety of GH therapy in ‘high risk’ patients (in particular children), including those with syndromes, diseases, and mutations known to be associated with an inherent elevated risk for cancer and early mortality (e.g. Neurofibromatosis type 1, Fanconi anaemia, or Down syndrome).